Aldeyra Therapeutics, Inc. develops medications for immune-mediated diseases, focusing on both ocular and systemic conditions. The company’s portfolio includes product candidates designed to inhibit inflammatory cells, addressing unmet medical needs. Aldeyra employs novel mechanisms of action to modulate immunological systems, aiming to optimize multiple pathways while minimizing toxicity. The company is engaged in multiple ongoing clinical trials to advance its investigational therapies.
